Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and … (NCT07057024) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
France120 participantsStarted 2026-02-12
Plain-language summary
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms.
As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities.
The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD).
The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
For all participants:
* Male or female, aged 18 to 60 years
* Subject having given their written consent to the study For Schizophrenia participants :
* Diagnosis of schizophrenia according to DSM-V criteria and stabilised for at least three months
For bipolar disorder participants :
\- Diagnosis of bipolar disorders according to DSM-V criteria and stabilised for at least three months
For depressive disorders participants :
\- Diagnosis of depressive disorders according to DSM-V criteria and stabilised for at least three months
Exclusion Criteria:
For all the participants :
* Subjects unable to give consent or not volunteering for the study.
* Current(s) somatic(s) condition(s)
* Specific ophthalmological problems (strabismus, amblyopia) incompatible with the devices stereoscopic (VR headsets)
* Head trauma's history with loss of consciousness
* Epilepsy history
* Intellectual disability
* Difficulties in understanding the French language
* Current or during the last 6 months of substance abuse or dependence (except tobacco)
* Freedom restriction by judicial or administrative decision and/or coercive hospitalisation
* Cybersickness history
* Pregnancy
For healthy control group :
* Current or previous psychiatric disorder
* Current psychotropic drug therapy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Record dwell time (millisecond) and saccadic parameters (millisecond and degree) using an eye-tracker connected to a virtual reality HMD. Then, compare each measure to identify schizophrenia, bipolar, depression and control group differences.
Timeframe: 90 minutes
Trial details
NCT IDNCT07057024
SponsorEtablissement Public de Santé Barthélemy Durand